New pyrrolo[2,1-f]purine-2,4-dione and imidazo[2,1-f]purine-2,4-dione derivatives as potent and selective human A3 adenosine receptor antagonists

Journal of Medicinal Chemistry

Volumn 48, Issue 14, 2005, Pages 4697-4701

  Baraldi, Pier Giovanni ^a   Preti, Delia ^a   Tabrizi, Mojgan Aghazadeh ^a   Fruttarolo, Francesca ^a   Romagnoli, Romeo ^a   Zaid, Naser Abdel ^b   Moorman, Allan R ^c   Merighi, Stefania ^a   Varani, Katia ^a   Borea, Pier Andrea ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b AN NAJAH NATIONAL UNIVERSITY   (Palestine)

^c King Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 BENZYL 3 PROPYL 1H,6H PYRROLO[2,1 F]PURINE 2,4 DIONE DERIVATIVE; 1 BENZYL 3 PROPYL 1H,8H IMIDAZO[2,1 F]PURINE 2,4 DIONE DERIVATIVE; 1 BENZYL 7 METHYL 3 PROPYL 1H,8H IMIDAZO[2,1 F]PURINE 2,4 DIONE; ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE A3 RECEPTOR ANTAGONIST; ADENOSINE RECEPTOR; IMIDAZO[2,1 F]PURINE 2,4 DIONE DERIVATIVE; PURINE DERIVATIVE; PYRROLO[2,1 F]PURINE 2,4 DIONE DERIVATIVE; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG; XANTHINE;

ARTICLE; BINDING AFFINITY; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE;

ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; CYCLIC AMP; HUMANS; IMIDAZOLES; PURINES; PYRROLES; RADIOLIGAND ASSAY; RECEPTOR, ADENOSINE A3; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 22244459937     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm058008c     Document Type: Article

References (29)

1. Fredholm, B. B.; Arslan, G.; Halldner, L.; Kull, B.; Schulte, G.; Wasserman, W. Structure and function of adenosine receptors and their genes. Naunyn-Schmied. Arch. Pharm. 2000, 362, 364-374.
2. Fredholm, B. B.; Ijzerman, A. P.; Jacobson, K. A.; Klotz, K.-N.; Linden, J. Nomenclature and classification of adenosine receptors. Pharm. Rev. 2001, 53, 527-552.
3. 3 adenosine receptors: design of selective ligands and therapeutic prospects. Drugs Future. 1995, 20, 689-699.
4. 3 adenosine receptors on human eosinophils elevates intracellular calcium. Blood 1996, 88, 3569-3574.
5. 3 receptors: Novel ligands and paradoxical effects. Trends. Pharmacol. Sci. 1998, 19, 184-191.
6. 3 receptor stimulation and cerebral ischemia. Eur. J. Pharmacol. 1994, 263, 59-67.
7. 3 adenosine receptors: Protective vs damaging effects identified using novel agonists and antagonists. Drug. Dev. Res. 1998, 45, 113-124.
8. 3 adenosine receptors: new targets for cancer therapy and chemoprotection. Drug. Dev. Res. 2000, 50, 101-117.
9. 3 receptor: sustained cardioprotection. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 6995-6999.
10. 3 antagonists. Biochem. Biophys. Res. Commun. 1997, 232-317.
11. 3 receptor antagonists. Trends. Pharm. Sci. 2000, 21, 456-459.
12. Merighi, S.; Mirandola, P.; Varani, K.; Gessi, S.; Leung, E.; Baraldi, P. G.; Tabrizi, M. A.; Borea, P. A. A glance at adenosine receptors: novel target for antitumor therapy. Pharmacol. Ther. 2003, 100(1), 31-48.
13. 3 adenosine receptors in human lymphocytes: upregulation in T cell activation. Mol. Pharmacol. 2004, 65, 711-719.
14. 3 adenosine receptor. J. Cell. Phys. 2001, 186, 19-23.
15. 3 adenosine receptors in Jurkat T cells. Br. J. Pharmacol. 2001, 134, 116-126.
16. Merighi, S.; Varani, K.; Gessi, S.; Cattabriga, E.; Iannotta, V.; Uloglou, C.; Leung, E.; Borea, P. A. Pharmacological and biochemical characterization of adenosine receptors in the human malignant melanoma A375 cell line. Br. J. Pharmacol. 2001, 134, 1215-1226.
17. 3 antagonists. PCT Int. Appl. WO 2004000224, 2003.
18. 3 adenosine receptors reduces mouse intraocular pressure. Invest. Ophthalmol. Vis. Sci. 2002, 43, 3021-3026.
19. Baraldi, P. G.; Tabrizi, M. A.; Fruttarolo, F.; Bovero, A.; Avitabile, B.; Preti, D.; Romagnoli, R.; Merighi, S.; Gessi, S.; Varani, K.; Borea, P. A. Recent Developments in the Field of A3 Adenosine Receptor Antagonists. Drug. Dev. Res. 2003, 58, 315-329.
20. 3 Receptor Ligands. Curr. Top. Med. Chem. 2003, 3, 445-462.
21. 3 adenosine receptor antagonists. J. Med. Chem. 2002, 45, 770-780.
22. Drabczyñska, A.; Schumacher, B.; Müller, C. E.; Karolak-Wojciechowska, J.; Michalak, B.; Pèkala, E.; Kieæ- Kononowicz, K. Impact of the aryl substituent kind and distance from pyrimido[2,1-f]purindiones on the adenosine receptor selectivity and antagonistic properties. Eur. J. Med. Chem. 2003, 38, 397-402.
23. 3 adenosine receptor antagonists. J. Med. Chem. 2002, 45, 3337-3344.
24. 3-adenosine receptor antagonists. J. Med. Chem. 2002, 45, 3440-3450.
25. Baraldi, P. G.; Abdel, Z. N.; Fruttarolo, F.; Tabrizi, A. M.; Nuñez, M.; Spalluto, G.; Romagnoli, R. A synthetic approach for the preparation of rigid analogues of 1,3-dipropyl-7-methyl-8-aryl/heteroarylstyryl xanthine. Synthesis 2001, 5, 773-777.
26. 6-[(dimethylamino)methylene] protection. Synthesis 2001, 3, 478-482.
27. Holschbach, M. H.; Fein, T.; Krummeich, C.; Lewis, R. G.; Wutz, W.; Schwabe, U.; Unterlugauer, D.; Olsson, R. A. A1 Adenosine Receptor Antagonists as Ligands for Positron Emission Tomography (PET) and Single-Photon Emission Tomography (SPET). J. Med. Chem. 1998, 41, 555-563.
28. Kramer, G. L.; Garst, J. E.; Mitchel, S. S.; Wells, J. N. Selective inhibition of cyclic nucleotide phosphodiesterases by analogues of 1-methyl-3-isobutylxanthine. Biochemistry 1977, 16, 3316-3321.
29. 3 adenosine receptors. Mol. Pharmacol. 2000, 57, 968-975.